Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Comments and Responses

Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension

Response to Ng et al.

  1. Dawn Smiley, MD and
  2. Guillermo Umpierrez, MD
  1. From the Endocrinology Section, Emory University, Atlanta, Georgia
  1. Address correspondence to Guillermo E. Umpierrez, MD, Endocrinology Section, Emory University, 49 Jesse Hill Jr. Dr., Atlanta, Georgia
Diabetes Care 2008 Jan; 31(1): e3-e3. https://doi.org/10.2337/dc07-1902
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Response to Ng et al.

We reported that hypertension affects nearly 70% of patients with type 2 diabetes at our institution and that 45% of them require three or more antihypertensive agents (1). Despite the multidrug approach, one-third of patients do not achieve the recommended blood pressure goal of <130/80 mmHg. These findings led us to investigate the prevalence of primary hyperaldosteronism (PHA), the most common cause of endocrine hypertension, in diabetic patients with resistant hypertension. We found that 14% of diabetic patients with resistant hypertension had biochemical evidence of PHA. Thus, select patients with diabetes should be screened for PHA, and this in turn may lead to improvement in cardiovascular outcomes.

We acknowledge the viewpoints of Ng et al. (2), and we agree that it would be of great therapeutic relevance to know whether there are long-term differences between subjects with essential hypertension and those with PHA as it relates to cardiovascular injury and mortality. More than 80% of patients with type 2 diabetes have features of metabolic syndrome, and 40–70% of patients with surgically treated aldosterone-producing adenomas have long-term hypertension (3). Thus, we hypothesize that the early diagnosis and treatment of PHA in diabetic patients with resistant hypertension may afford them even better cardiovascular outcomes.

As Ng et al. outlined, we also agree that further investigations should be done related to screening and diagnosis of PHA in patients with type 2 diabetes. There are currently no studies to guide appropriate cutoff values for plasma aldosterone (PAC) or plasma renin activity for screening patients with diabetes or obesity. Similarly, there is no uniform acceptance of a best test to confirm diagnosis of PAH. The screening PAC–to–plasma renin activity ratio cutoff of >30 ng · ml−1 · h−1 and post–sodium load PAC cutoff of ≥5.0 ng/dl were arbitrarily selected from previously published diagnostic ranges noted in the general population (4,5).

Historically, most cases of PHA have been attributed to unilateral aldosterone-producing adenomas; however, we now know that the majority of PHA cases are most likely attributable to bilateral adrenal hyperplasia (5,6). Medical management with aldosterone antagonists is the treatment of choice for patients with bilateral adrenal hyperplasia. Independent of the antihypertensive effects, aldosterone blockade has been shown to improve potassium balance and decrease mortality in heart failure cases (7). Two-thirds of our study cohort had bilateral disease, and we are currently evaluating response to medical management as it relates to long-term renal and cardiovascular outcomes.

In conclusion, PAH is common in diabetic patients with resistant hypertension. Our study indicates that diabetic subjects with poorly controlled hypertension on three or more antihypertensive drugs should be screened for aldosteronism. Research is needed to better establish optimal diagnostic cutoffs and the true prevalence of PAH in patients with and without diabetes.

Footnotes

  • DIABETES CARE

References

  1. ↵
    Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A: Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 30:1699–1703, 2007
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Ng YW, Tiu SC, Ng JCM, Chan HY: Primary aldosteronism in diabetic subjects with resistant hypertension (Letter). Diabetes Care 31:e2, 2008. DOI: 10.2337/dc07-1740
    OpenUrlFREE Full Text
  3. ↵
    Sawka AM, Young Jr WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135:258–261, 2001
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Schwartz GL, Turner ST: Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51:386–394, 2005
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Young WF Jr: Minireview: primary aldosteronism: changing concepts in diagnosis and treatment. Endocrinology 144:2208–2213, 2003
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. JCEM 89:1045–1050, 2004
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 131:105–108, 1999
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 31 (1)

In this Issue

January 2008, 31(1)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
Dawn Smiley, Guillermo Umpierrez
Diabetes Care Jan 2008, 31 (1) e3; DOI: 10.2337/dc07-1902

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
Dawn Smiley, Guillermo Umpierrez
Diabetes Care Jan 2008, 31 (1) e3; DOI: 10.2337/dc07-1902
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Cigarette Smoking Is Associated With Low Glomerular Filtration Rate in Male Patients With Type 2 Diabetes
Show more Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.